Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: TA8995

Dezima Pharma – anti-dyslipidemic compounds

Posted on by

Dezima Pharma is a biopharma company developing novel drugs to treat dyslipidemia.

Dezima Pharma – anti-dyslipidemic compounds

dezima pharma

Continue reading →

Posted in Biotech Companies, Biotech Companies Netherlands | Tagged anti-dyslipidemic compound, anti-dyslipidemic compounds, BioGeneration Ventures, Bryan Brewer, cardiovascular disease, CETP, CETP inhibitor, cholesteryl ester transfer protein, cholesteryl ester transfer protein inhibitor, DEZ-001, DEZ001, Dezima, Dezima Pharma, Dezima Pharma - anti-dyslipidemic compounds, dyslipidemia, dyslipidemic, Forbion Capital Partner, HDL, high-density lipoprotein, John Ford, John Kastelein, LDL, lipoprotein, low-density lipoprotein, Marco Boorsma, Patrick Round, Philip Barter, Rob de Ree, Sander Slootweg, Sander van Deventer, Somu Subramaniam, TA-8995, TA8995, Wil Hazenberg

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress